摘要
Objectives:Allergic rhinitis(AR)refers to a form of respiratory inflammation that mainly affects the sinonasal mucosa.The purpose of this study was to explore the level of immune cell infiltration and the pathogenesis of AR.Methods:We performed a comprehensive analysis of two gene expression profiles(GSE50223 and GSE50101,a total of 30 patients with AR and 31 healthy controls).CIBERSORT was used to evaluate the immune cell infiltration levels.Weighted gene coexpression network analysis was applied to explore potential genes or gene modules related to immune status,and enrichment analyses including gene ontology,Kyoto Encyclopedia of Genes and Genomes,gene set enrichment analysis,and gene set variation analysis,were performed to analyze the potential mechanisms in AR.A protein–protein interaction network was constructed to investigate the hub genes,and consensus clustering was conducted to identify the molecular subtypes of AR.Results:Compared to the healthy controls,patients with AR had high abundance levels and proportions of CD4+memory‐activated T cells.One hundred and eight immune‐related differentially expressed genes were identified.Enrichment analysis suggested that AR was mainly related to leukocyte cell‐cell adhesion,cytokine‐cytokine receptor interaction,T‐cell activation,and T‐cell receptor signaling pathway.Ten hub genes,includingTYROBP,CSF1R,TLR8,FCER1G,SPI1,ITGAM,CYBB,FCGR2A,CCR1,andHCK,which were related to immune response,might be crucial to the pathogenesis of AR.Three molecular subtypes with significantly different immune statuses were identified.Conclusion:This study improves our understanding of the molecular mechanisms in AR via comprehensive strategies and provides potential diagnostic biomarkers and therapeutic targets of AR.
基金
Beijing Health Technologies Promotion Program(Grant/Award Number:BHTPP202007)
Research and Development Foundation of Peking University People’s Hospital(Grant/Award Number:RDL2021‐05)
Capital Health Research and Development of Special Fund(Grant/Award Number:2020‐1‐2051)。